Why the study?
Do non-vitamin K antagonist oral anticoagulants provide benefits compared with warfarin for stroke prevention in elderly atrial fibrillation patients with multiple comorbid conditions?
Do non-vitamin K antagonist oral anticoagulants provide benefits compared with warfarin for stroke prevention in elderly atrial fibrillation patients with multiple comorbid conditions?
This review highlights the benefits of non-vitamin K antagonist oral anticoagulants compared to warfarin for stroke prevention in frail, elderly patients with atrial fibrillation and multiple comorbidities.
Answers are grounded in this paper and cite their sources.
May support NOAC preference over warfarin in frail elderly AF; leaves open need for dedicated RCTs.
Stroke prevention in elderly atrial fibrillation patients remains a challenge. There is a high risk of stroke and systemic thromboembolism but also a high risk of bleeding if anticoagulants are prescribed. The elderly have increased chronic kidney disease, coronary artery disease, polypharmacy, and overall frailty. For all these reasons, anticoagulant use is underutilized in the elderly. In this manuscript, the benefits of non-vitamin K antagonist oral anticoagulants compared with warfarin in the elderly patient population with multiple comorbid conditions are reviewed.
No takes yet. Share an insight, caveat, or question.
Flaker et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: